Table 2.

Reinduction therapies, stem cell transplantations, treatment-related deaths, relapse, and survival for 75 patients* with relapsed BL/B-AL between 2001 and 2016

ReinductionCC/AA-basedR-ICER-ICI/ICNVICI/ICITEPOCHOther
Patients 27 10 15 11 
Rituximab 16 (/25) 10 15 
TRD before SCT 
Progression before SCT 13 
SCT 20* 6* 11 
Kind of SCT Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo 
 12 8 2 11 
TRD after SCT   
Relapse after SCT   
Survival 4* 2  10  
ReinductionCC/AA-basedR-ICER-ICI/ICNVICI/ICITEPOCHOther
Patients 27 10 15 11 
Rituximab 16 (/25) 10 15 
TRD before SCT 
Progression before SCT 13 
SCT 20* 6* 11 
Kind of SCT Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo 
 12 8 2 11 
TRD after SCT   
Relapse after SCT   
Survival 4* 2  10  

allo, allogeneic SCT; auto, autologous SCT; CR, complete remission; TRD, treatment-related death.

*

Exclusion: 1 patient without data on treatment, 1 patient who died immediately at relapse, 2 patients who received palliative care.

SCT after second relapse/progression during reinduction: CC: 3 patients (2× auto - death of disease, 1× allo - CR), ICE: 2 patients (2× allo - death of disease).

One patient: isolated testicular relapse.

Close Modal

or Create an Account

Close Modal
Close Modal